Is VBP the new VBC for U.S. Drug Prices?
All U.S. healthcare stakeholders recognize that the overheated drugs market is not sustainable. The ever-growing spiral of rising gross prices, often accompanied by increasing rebates and returns, is not a model fit for purpose now, let alone the future.
So, what are the alternatives?
While value-based contracting (VBC) has had some great success in the U.S., the opportunity to introduce value-based pricing (VBP) could be on the horizon. In this compelling and original report by Verpora’s expert thought leaders, the role that VBP and VBC can play in the future of drug pricing is examined.
Download this insightful report now - no charge
Disclaimer
Content in this article is based on secondary market research using externally sourced data available in the public domain. Opinions and commentary are those of the authors and do not reflect views of any commercial organisation or government body mentioned in the article. For any questions relating to the article please contact adam.meads@verpora.com.
